The Neuroendocrine Transition in Prostate Cancer Is Dynamic and Dependent on ASCL1

Transplanted mouse prostate organoids with human-relevant driver mutations develop adenocarcinomas, but only those with Rb1 deletion advance to aggressive, ASCL1+ neuroendocrine prostate cancer resistant to androgen receptor signaling inhibitors.